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Patients receiving hemodialysis have high rates of
cardiovascular morbidity and mortality that may be related
to the hemodynamic effects of rapid ultrafiltration. Here we
tested whether higher dialytic ultrafiltration rates are
associated with greater all-cause and cardiovascular
mortality, and hospitalization for cardiovascular disease. We
used data from the Hemodialysis Study, an almost-7-year
randomized clinical trial of 1846 patients receiving thrice-
weekly chronic dialysis. The ultrafiltration rates were divided
into three categories: up to 10ml/h/kg, 10–13ml/h/kg, and
over 13ml/h/kg. Compared to ultrafiltration rates in the
lowest group, rates in the highest were significantly
associated with increased all-cause and cardiovascular-
related mortality with adjusted hazard ratios of 1.59 and 1.71,
respectively. Overall, ultrafiltration rates between 10–13ml/h/
kg were not associated with all-cause or cardiovascular
mortality; however, they were significantly associated among
participants with congestive heart failure. Cubic spline
interpolation suggested that the risk of all-cause and
cardiovascular mortality began to increase at ultrafiltration
rates over 10ml/h/kg regardless of the status of congestive
heart failure. Hence, higher ultrafiltration rates in
hemodialysis patients are associated with a greater risk of
all-cause and cardiovascular death.
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The United States is home to more than 350,000 hemodia-
lysis (HD) patients.1 Dialysis patients experience high rates of
mortality, driven largely by an exceptionally high rate
of cardiovascular (CV)-related mortality, which exceeds that
of the general population by 10- to 20-fold.2,3 Dialysis
patients have a high prevalence of traditional CV risk factors
such as diabetes and hypertension, as well as a number of
additional risk factors related to their kidney dysfunction
and/or to the dialytic procedure such as autonomic
dysfunction, vascular calcification and stiffness, and increased
levels of circulating inflammatory mediators.1,4,5 Unfortu-
nately, many of these factors have proven to be either
non-modifiable or difficult to modify within the scope of
current dialytic practice.
One compelling and potentially modifiable putative CV risk
factor is ultrafiltration rate (UFR; the rate at which fluid is
removed during the course of dialysis). As native kidney
function wanes, ultrafiltration is necessary to maintain volume
control (i.e., salt and water balance), but it simultaneously and
disadvantageously promotes non-physiological fluid shifts and
hemodynamic instability. In turn, these factors contribute to
tissue ischemia, maladaptive cardiac structural changes, myo-
cardial stunning, arrhythmia, and cardiac sudden death.6–14
Despite obvious biological plausibility, the association between
UFR and CV morbidity and mortality has not been well
studied. The only previous study in this regard examined UFR
410 (versus p10) ml/h/kg, showing a small increase in all-
cause mortality (adjusted RR¼ 1.09; P¼ 0.02) but no increase
in cardiopulmonary mortality (adjusted RR¼ 1.04; P¼ 0.41).15
Subsequent data suggest that the cut point of 10ml/h/kg may
have been too low to observe a true UFR–CV mortality
association,16 and the issue remains unsettled.
Therefore, we undertook this study in order to clarify the
associations between UFR and both all-cause and CV-related
mortality among patients undergoing chronic, thrice-weekly
HD. We hypothesized that higher UFR would be associated
with greater CV-related mortality that, in turn, would drive
all-cause mortality. We used the data from the Hemodialysis
Study (HEMO), as this study is one of very few large-scale
prospective studies in chronic dialysis patients in which the
CV outcomes were rigorously adjudicated according to
standardized criteria.17 Moreover, we sought to leverage
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these data to identify a threshold at which higher UFR may
be detrimental to CV health and survival.
RESULTS
Baseline characteristics of cohort
Demographic, clinical, and biochemical characteristics of the
study population are shown in Table 1. Overall, the cohort
consisted of 1,846 patients with a mean age of 57.6±14.0
years; 56.2% were women and 62.6% were black. At baseline
39.7% of the patients carried a diagnosis of congestive heart
failure, 39.3% had ischemic heart disease and 44.6% were
diabetic.
The mean UFR for the cohort was 12.1±4.6ml/h/kg; 644
(34.9%), 517 (28.0%), and 685 (37.1%) patients had UFR
p10, 10–13, and 413ml/h/kg, respectively. Overall, UFR
groups were similar in terms of sex, race, dialysis vintage,
smoking status, access type, treatment group assignment (flux
and Kt/V), diabetes, ischemic heart disease, peripheral vascular
disease, serum albumin, and use of most classes of anti-
hypertensive agents (Table 1). At baseline, patients with high
UFRs were younger, more likely to have congestive heart failure
and oliguria, and less likely to have cerebrovascular disease;
they tended to have higher systolic blood pressures, serum
creatinine and phosphate concentrations, and lower hemato-
crits. Not surprisingly, high UFR was associated with increased
interdialytic weight gain and shorter HD session length.
Associations between UFR and all-cause and CV mortality
Overall, 871 deaths occurred during 5,233 patient-years of at-
risk time; 343 of these deaths were due to CV causes. The
median survival time was 2.5 years. Compared with UFR
p10ml/h/kg, UFR 413ml/h/kg was significantly associated
with all-cause mortality: unadjusted hazard ratio (HR) (95%
confidence interval (CI)) 1.20 (1.03–1.41) (Figure 1). When
multivariable adjustment was used to account for baseline
differences between groups, this association was greatly
potentiated: HR (95% CI) 1.59 (1.29–1.96). UFR 10–13ml/
h/kg bore an intermediate association with CV mortality that
was not statistically significant: adjusted HR (95% CI) 1.06
(0.87–1.28). Results were similar when UFRs following the
long interdialytic break were excluded from consideration,
when the referent group was restricted to participants with
UFR 8–10ml/h/kg (data not shown), and when flux and Kt/V
treatment group assignments were included as covariates in
the statistical model (Supplementary Table SA online).
Similarly, compared with UFR p10ml/h/kg, UFR
413ml/h/kg was associated with increased CV mortality:
unadjusted HR (95% CI) 1.33 (1.03–1.72) (Figure 2).
Upon multivariable adjustment, this association was greatly
potentiated: adjusted HR (95% CI) 1.71 (1.23–2.38). UFR
10–13ml/h/kg bore an intermediate association with CV
mortality that was not statistically significant: adjusted HR
(95% CI) 1.06 (0.78–1.44). Again, results were similar when
UFRs following the long interdialytic break were excluded
from consideration, when the referent group was restricted to
participants with UFR 8–10ml/h/kg (data not shown), and
when flux and Kt/V treatment group assignments were
included as covariates in the statistical model (Supplemen-
tary Table SA online).
The data suggested effect modification of the UFR–mor-
tality and UFR–CV mortality associations on the basis of
congestive heart failure. Specifically, UFR between 10 and
13ml/kg/h was associated with greater all-cause mortality
and nearly associated with greater CV mortality among
patients with congestive heart failure, but was not among
patients without congestive heart failure (Table 2). The
estimates for UFR 413ml/kg/h did not appear to be
materially affected by the presence or absence of congestive
heart failure; point estimates of both groups were similar to
those from the primary analyses. No effect modification on
the basis of oliguria, arterial disease (coronary, cerebral, or
peripheral arterial), or HEMO Study treatment group
assignment (flux or dose) was detected (data not shown).
Secondary analyses
In order to more fully examine the threshold(s) at which
UFR may become harmful, we conducted analyses in which
we examined the association of UFR, represented as a cubic
spline, with CV and all-cause mortality. As demonstrated in
Figure 3, the HRs for both CV and all-cause mortality rose
sharply at values between 10 and 14ml/h/kg, and to a less
pronounced degree at higher values. Consistent with results
of the primary analysis, the HR for CV mortality was greater
than that for all-cause mortality at all values of UFR.
In order to examine the association between UFR and CV-
related morbidity, we conducted time-to-event analyses in
which the outcomes of interest were (1) hospitalization for
CV disease or all-cause mortality (n¼ 1081); (2) hospitaliza-
tion for CV disease or CV mortality (n¼ 843); and (3)
hospitalization for CV disease (n¼ 742). In total, participants
contributed 3762 patient-years of at-risk time with a median
survival time of 1.5 years. In each instance, UFR413ml/kg/h
was potently and significantly associated with a greater
hazard for outcome, whereas UFR 10–13ml/kg/h was not
(Figure 4).
DISCUSSION
Despite the highly plausible biological link between dialytic
ultrafiltration and CV morbidity and mortality, such an
association has not been previously described in the
literature. In this report we demonstrated for the first time
that higher UFRs are associated with greater CV (as well as
all-cause) mortality. Risk for CV hospitalization and
composite CV hospitalization/mortality end points followed
a similar pattern. Cubic spine analysis further substantiated
these findings, revealing a steep rise in the risk for all-cause
and CV mortality at UFRs 410ml/h/kg.
Only one previous study has examined the association
between UFR and CV mortality, failing to show a significant
difference in risk between participants with UFRp10 versus
410ml/h/kg.15 Subsequent work (which considered all-
cause but not CV mortality) suggested that a threshold of
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Table 1 | Baseline characteristics of the overall study cohort and comparisons across ultrafiltration groupsa
Total (N=1846b) p10ml/h/kg (n=644b) 10–13ml/h/kg (n=517b) 413ml/h/kg (n=685b) Pc
UFR (ml/h/kg) 12.1 (4.6) 7.7 (1.8) 11.4 (8.6) 16.8 (3.6) —
Age (years) 57.6 (14.0) 60.4 (13.2) 57.9 (13.5) 54.8 (14.7) o0.001
Female 1038 (56.2%) 367 (57.0%) 272 (52.6%) 399 (58.3%) 0.13
Black 1156 (62.6%) 405 (62.9%) 324 (62.7%) 427 (62.3%) 0.98
Smoking 0.28
Never 926 (50.2%) 336 (52.3%) 257 (49.8%) 333 (48.7%) —
Past 597 (32.4%) 205 (31.9%) 176 (34.1%) 216 (31.6%) —
Current 320 (17.4%) 102 (15.9%) 83 (16.1%) 135 (19.7%) —
(N=1843) (n=643) (n=516) (n=684)
Vintage (years) 0.12
o1 490 (26.5%) 180 (28.0%) 135 (26.1%) 175 (25.6%) —
1–2 382 (20.7%) 147 (22.8%) 109 (21.1%) 126 (18.4%) —
2–4 434 (23.5%) 136 (21.1%) 134 (25.9%) 164 (23.9%) —
X4 540 (29.3%) 181 (28.1%) 139 (26.9%) 220 (32.1%) —
Access 0.57
Graft 1112 (60.2%) 391 (60.7%) 301 (58.2%) 420 (61.3%) —
Fistula 612 (33.2%) 205 (31.8%) 184 (35.6%) 223 (32.6%) —
Catheter 122 (6.6%) 48 (7.5%) 32 (6.2%) 42 (6.1%) —
Oliguricd 1579 (86.3%) 524 (82.0%) 444 (86.4%) 611 (90.3%) o0.001
(N=1830) (n=639) (n=514) (n=677)
SBP (mmHg) 0.001
o120 99 (5.4%) 41 (6.4%) 28 (5.4%) 30 (4.4%) —
120–140 438 (23.7%) 162 (25.2%) 140 (27.1%) 136 (19.9%) —
140–160 667 (36.1%) 247 (38.4%) 181 (35.0%) 239 (34.9%) —
160–180 490 (26.5%) 148 (23.0%) 136 (26.3%) 206 (30.1%) —
X180 152 (8.2%) 46 (7.1%) 32 (6.2%) 74 (10.8%) —
Diabetes 823 (44.6%) 290 (45.0%) 242 (46.8%) 291 (42.5%) 0.32
Congestive heart failure 733 (39.7%) 240 (37.3%) 192 (37.1%) 301 (43.9%) 0.02
Ischemic heart disease 726 (39.3%) 251 (39.0%) 212 (41.0%) 263 (38.4%) 0.64
Cerebrovascular disease 360 (19.5%) 142 (22.1%) 104 (20.1%) 114 (16.6%) 0.04
Peripheral vascular disease 474 (25.7%) 165 (25.6%) 142 (27.5%) 167 (24.4%) 0.48
Albumin (g/dl) 3.6 (0.4) 3.6 (0.3) 3.6 (0.4) 3.6 (0.4) 0.63
Creatinine (mg/dl) 10.3 (2.9) 10.0 (2.7) 10.6 (2.9) 10.3 (3.0) 0.005
(N=1845) (n=684)
Hematocrit (%) 0.001
o30 334 (18.1%) 84 (13.1%) 96 (18.6%) 154 (22.5%) —
30–33 438 (23.8%) 153 (23.8%) 115 (22.3%) 170 (24.8%) —
33–36 545 (29.6%) 209 (32.6%) 159 (30.8%) 177 (25.8%) —
X36 526 (28.5%) 196 (30.5%) 146 (28.3%) 184 (26.9%) —
(N=1843) (n=642) (n=516)
Phosphorous (mg/dl) 5.8 (1.9) 5.7 (1.8) 5.7 (1.7) 6.0 (2.0) 0.001
(N=1844) (n=642)
ACEi/ARB use 484 (26.2%) 152 (23.6%) 124 (24.0%) 208 (30.4%) 0.008
a-1 blocker use 125 (6.8%) 51 (7.9%) 33 (6.4%) 41 (6.0%) 0.34
b-Blocker use 553 (30.0%) 180 (28.0%) 151 (29.2%) 222 (32.4%) 0.19
Calcium channel blocker use 910 (49.3%) 292 (45.3%) 247 (47.8%) 371 (54.2%) 0.004
Nitrate use 317 (17.2%) 112 (17.4%) 81 (15.7%) 124 (18.1%) 0.53
Other antihypertensive use 416 (22.5%) 127 (19.7%) 121 (23.4%) 168 (24.5%) 0.10
IDWG (kg) 2.9 (1.1) 2.1 (0.9) 3.0 (0.9) 3.6 (1.0) o0.001
Session length (min) 218 (24) 226 (21) 220 (23) 209 (23) o0.001
BMI (kg/m2) o0.001
o18.5 125 (6.8%) 20 (3.1%) 21 (4.1%) 84 (12.3%) —
18.5–24.9 896 (48.8%) 233 (36.4%) 230 (44.8%) 433 (63.5%) —
25–29.9 519 (28.3%) 227 (35.4%) 165 (32.1%) 127 (18.6%) —
X30 297 (16.2%) (n=1837) 161 (25.1%) (n=641) 98 (19.1%) (n=514) 38 (5.6%) (n=684) —
High Kt/V group 920 (49.8%) 323 (50.2%) 248 (48.0%) 349 (51.0%) 0.58
High flux group 921 (49.9%) 329 (51.1%) 246 (47.6%) 346 (50.5%) 0.46
Abbreviations: ACEi/ARB, angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker; BMI, body mass index; IDWG, interdialytic weight gain; SBP, systolic
blood pressure; UFR, ultrafiltration rate.
aValues presented as mean (s.d.) or n (%).
bExcept where noted.
cAcross UFR groups, determined by analysis of variance for continuous variables and w2-testing for categorical variables.
dUrine output p200ml/day.
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10ml/h/kg may have been too low to demonstrate a true
association.16 Correspondingly, our categorical analysis
demonstrated a significant association between CV mortality
and UFR 413ml/h/kg, but not 10–13ml/h/kg. However,
cubic spline interpolation indicated that the risk of CV death
does begin to rise when UFR exceeds B10ml/h/kg, sug-
gesting that the absence of association in the 10–13ml/h/kg
stratum derived from the modest effects of those UFRs that
were close to 10 and from the modest sample size of this
stratum (517 participants, 82 CV-deaths). Interestingly, our
data suggest effect modification of the UFR–mortality and
UFR–CV mortality associations on the basis of congestive
heart failure, suggesting that even modestly elevated UFR
(10–13ml/h/kg) may be disadvantageous in these high-risk
patients.
The association between higher UFR and increased CV
morbidity and mortality should not be surprising. During
dialysis, fluid is removed directly from the vascular space;
when dialytic removal outpaces resorption from other
compartments, circulating volume is reduced and transient
myocardial ischemia can result. This effect is amplified by
limitations in cardiac reserve and autonomic dysfunction,
both of which are common among HD patients.18–22
Previous research has demonstrated that transient ischemia
during dialysis can result in ‘myocardial stunning’ (regional
wall motion abnormalities) and associated compromises in
cardiac contractility, systolic function, and survival.8,23–25 In
Burton’s analysis, higher ultrafiltration volumes were asso-
ciated with the presence of HD-induced regional wall motion
abnormalities (P¼ 0.01),8 providing a plausible mechanism
for the strong association between high UFRs and CV
mortality demonstrated in our analyses. From animal studies,
it is known that repeated myocardial stunning triggers a
cascade of events, including myocardial hibernation, fibrosis,
and remodeling, which predispose to ventricular dysfunction
and arrhythmia.26 Ventricular dysfunction in dialysis patients
can be particularly hazardous as it has been linked to greater
hemodynamic instability during dialysis, which can result in
a vicious cycle of further myocardial stunning and cardiac
decline.23
There are two options to minimize UFR in current clinical
practice: (1) limit patients’ fluid intake and (2) allow more
time for fluid removal (i.e., extend dialysis time). Clinical
experience and published data demonstrate that interven-
tions aimed at reducing patients’ interdialytic fluid intake are
often ineffective.27,28 Moreover, in these analyses, we
demonstrate that greater UFRs are associated with poor
prognosis independent of (i.e., adjusted for) interdialytic
weight gain, suggesting that more gradual volume removal is
associated with improved outcomes regardless of the
magnitude of weight gain itself. In current practice, session
length is determined by indices of small molecule (i.e., urea)
clearance; UFR is adjusted to allow for necessary removal of
intercurrent fluid gains within this fixed time allotment. Our
findings suggest that perhaps UFR should factor more
prominently into determination of dialytic session length.
Such a model might involve session length titration on a
(near) session-to-session basis based on observed intradialytic
weight gain (with some floor level determined by considera-
tion of urea clearance). In addition, UFR might be minimized
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Figure 1 |Unadjusted and adjusted associations between
ultrafiltration rate (UFR) and all-cause mortality based on Cox
regression models. Multivariable models were adjusted for age,
sex, interdialytic weight gain, race (black, non-black), smoking
status (never, past, current), vintage (o1, 1–2, 2–4, X4 years),
access type (graft, fistula, catheter), systolic blood pressure (o120,
120–140, 140–160, 160–180, X180mmHg), residual urine output
(p versus 4200ml/day), diabetes, congestive heart failure,
peripheral vascular disease, ischemic heart disease,
cerebrovascular disease, serum albumin, creatinine, hematocrit
(o30, 30–33, 33–36, X36%), and phosphorus, and use of
a-adrenergic blocker, angiotensin-converting enzyme inhibitor/
angiotensin receptor blocker, b-blocker, calcium channel blocker,
nitrates, and other antihypertensives. Two-way cross-product
terms with time were included for albumin and systolic blood
pressure due to non-proportional hazards. Abbreviations: ref.,
reference; CI, confidence interval; HR, hazard ratio.
Association between UFR and CV mortality
1 (ref.) 1 (ref.)
UFR ml/h/kg
10
10–13
>13
0.
91
 (0
.68
–1
.21
)
1.
33
 (1
.03
–1
.72
)
1.
06
 (0
.78
–1
.44
)
1.
71
 (1
.23
–2
.38
)
H
R
 (9
5%
 C
I)
2.5
1.5
1
0.5
Unadjusted Adjusted
Figure 2 |Unadjusted and adjusted associations between
ultrafiltration rate (UFR) and cardiovascular (CV)-related
mortality based on Cox regression models. Multivariable
models were adjusted for age, sex, interdialytic weight gain, race
(black, non-black), smoking status (never, past, current), vintage
(o1, 1–2, 2–4, X4 years), access type (graft, fistula, catheter),
systolic blood pressure (o120, 120–140, 140–160, 160–180,
X180mmHg), residual urine output (p versus 4200ml/day),
diabetes, congestive heart failure, peripheral vascular disease,
ischemic heart disease, cerebrovascular disease, serum albumin,
creatinine, hematocrit (o30, 30–33, 33–36, X36%), and
phosphorus, and use of a-adrenergic blocker, angiotensin-
converting enzyme inhibitor/angiotensin receptor blocker,
b-blocker, calcium channel blocker, nitrates, and other
antihypertensives. A two-way cross-product term with time
was included for albumin due to non-proportional hazards.
Abbreviations: ref., reference; CI, confidence interval; HR, hazard
ratio.
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by more frequent dialysis (which allows less intervening
time for fluid accumulation) or by wearable ultrafiltration
technologies that enable fluid removal even during
the interdialytic interval; ongoing studies are examining the
feasibility and health effects of these approaches.29,30
Strengths of this study include the prospective and rigorous
data collection, standardized adjudication of death/hospitaliza-
tion events, and robust sample size in the HEMO Study. Several
limitations of this study bear mention. As with any observa-
tional analysis, there exists the potential for residual confound-
ing and bias. To minimize risk for residual confounding, we
adjusted estimates for variables plausibly associated with both
UFR and mortality, such as age, gender, comorbid conditions,
dialysis access type, and antihypertensive medication use;
however, we cannot exclude the possibility of residual confound-
ing on the basis of these variables or by other variables not
considered. A second weakness may be in our use of observed
rather than prescribed UFR as this may have introduced
misclassification bias into our UFR calculation (e.g., hypo-
tension-necessitated fluid boluses would decrease pre-to-post
session weight change, thus underestimating the rate at which
fluid was actually removed during treatment); likewise, changes
in UFR within individual participants after baseline may have
also resulted in misclassification. Such misclassification,
however, would be expected to bias findings toward the null,
rendering our estimates conservative. Finally, the HEMO
Study excluded the very elderly (480 years old), patients
with New York Heart Association Class IV heart failure and
unstable angina, and most patients 4100 kg (on the basis of
inability to achieve target Kt/V), which may limit general-
izability to these sub-populations.17 Nonetheless, we believe
that our results apply to the vast majority of the overall US
HD population.
In conclusion, this study shows that among chronic HD
patients, UFRs 413ml/h/kg are associated with increased
all-cause mortality and even more so with CV mortality.
Further prospective studies are needed to confirm and
generalize findings and to investigate interventional strategies
aimed at mitigating CV risk through minimization of UFR.
Table 2 | Effect modification of the association between UFR and all-cause and CV mortality on the basis of congestive heart
failure
Congestive heart failure () Congestive heart failure (+)
UFR Adjusted HR (95% CI)a P Adjusted HR (95% CI)a P P-interactionb
All-cause mortality 0.002
p10ml/h/kg 1.00 (ref.) — 1.00 (ref.) — —
10–13ml/h/kg 0.80 (0.64–1.05) 0.11 1.41 (1.09–1.81) 0.008 —
413ml/h/kg 1.61 (1.23–2.11) 0.001 1.59 (1.24–2.05) 0.008 —
CV-related mortalityc 0.07
p10ml/h/kg 1.00 (ref.) — 1.00 (ref.) — —
10–13ml/h/kg 0.76 (0.48–1.20) 0.24 1.41 (0.94–2.11) 0.10 —
413ml/h/kg 1.70 (1.11–2.62) 0.02 1.73 (1.15–2.59) 0.008 —
Abbreviations: CI, confidence interval; CV, cardiovascular; HR, hazard ratio; ref., reference; SBP, systolic blood pressure; UFR, ultrafiltration rate.
aModels adjusted for age, sex, interdialytic weight gain, race (black, non-black), smoking status (never, past, current), vintage (o1, 1–2, 2–4, X4 years), access type (graft,
fistula, catheter), SBP (o120, 120–140, 140–160, 160–180,X180mmHg), residual urine output (pversus4200ml/day), diabetes, congestive heart failure, peripheral vascular
disease, ischemic heart disease, cerebrovascular disease), serum albumin, creatinine, hematocrit (o30, 30–33, 33–36, X36%), and phosphorus, and use of a-adrenergic
blocker, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, b-blocker, calcium channel blocker, nitrates, and other antihypertensives. Two-way
cross-product terms with time were included for albumin and SBP in analyses of all-cause mortality and for albumin in analyses of CV-related mortality due to non-
proportional hazards.
bBased on likelihood ratio testing.
cCV events were those attributed to ischemic heart disease, congestive heart failure, arrhythmias and conduction problems, sudden cardiac death due to heart conditions
other than ischemic heart disease/arrhythmia, valvular defects, hypertensive crisis, or accelerated hypertension, cerebral vascular disease, and vascular disease, including
ruptured vascular aneurysm, peripheral vascular disease, mesenteric ischemia, and arterial embolism and thrombosis.
Associations between UFR and CV and all-cause mortality
Ad
jus
ted
 ha
za
rd 
rat
io
2
1.8
1.6
1.4
1.2
1
CV mortality
All-cause mortality
UFR (ml/h/kg)
5 10 15 20
Figure 3 |Cubic spline analysis of the associations between
ultrafiltration rate (UFR) and cardiovascular (CV) (solid line)
and all-cause (dashed line) mortality. Hazard ratios were
adjusted for age, sex, interdialytic weight gain, race (black, non-
black), smoking status (never, past, current), vintage (o1, 1–2, 2–4,
X4 years), access type (graft, fistula, catheter), systolic blood
pressure (o120, 120–140, 140–160, 160–180, X180mmHg),
residual urine output (p versus 4200ml/day), diabetes,
congestive heart failure, peripheral vascular disease, ischemic
heart disease, cerebrovascular disease, serum albumin, creatinine,
hematocrit (o30, 30–33, 33–36,X36%), and phosphorus, and use
of a-adrenergic blocker, angiotensin-converting enzyme inhibitor/
angiotensin receptor blocker, b-blocker, calcium channel blocker,
nitrates, and other antihypertensives. Estimates are presented for
UFRs between 5.8ml/h/kg (the 5th percentile of observed UFR in
the study sample) and 20.4ml/h/kg (the 95th percentile).
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METHODS
Study design
This study was deemed exempt by the Partners Health Care
Institutional Review Board. All study data were derived from the
HEMO Study, and were obtained from the National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK) data
repository with permission from the NIDDK. The HEMO Study
was a 2 2 factorial multicenter randomized trial to evaluate the
effects of dialysis dose and membrane flux on clinical outcomes. The
design and methods have been previously reported.17,31 Briefly, all
participants had been on HD for at least 3 months, continued to
receive HD thrice-weekly, and were between the ages of 18 and 80
years; they were enrolled between March 1995 and October 2000 at
15 clinical centers; maximum potential follow-up time was 6.6
years.17,31 Notable HEMO exclusion criteria included New York
Heart Association class IV heart failure despite maximal therapy,
unstable angina pectoris, and failure to achieve an equilibrated
Kt/V of 1.3 in o4.5 h during two consecutive dialysis sessions (an
exclusion that led to 97% of randomized patients being o100 kg).
Data collection
Per HEMO protocol, all study data were obtained via subject
interviews, medical chart reviews, and self-reported questionnaires.
Demographics including age, sex, race, and time since the start of
dialysis (vintage) were assessed at baseline. Existence of comorbid
medical conditions, including diabetes, congestive heart failure,
ischemic heart disease, cerebrovascular disease, peripheral vascular
disease, and tobacco use, was assessed at baseline, week 5, and then
annually. Dialysis treatment parameters (including ultrafiltration
volume, treatment duration, vascular access type, and intradialytic
symptoms), physiological parameters (including residual urine
output and pre-, post-, and intradialytic blood pressures), relevant
laboratory measures (including serum albumin, creatinine,
phosphate, and hematocrit), and medication use (including
angiotensin-converting enzyme inhibitors, angiotensin receptor
blockers, b-blockers, calcium channel blockers, nitrates, and other
antihypertensive) were measured at baseline and then monthly.
All deaths and all hospitalizations incurred by HEMO partici-
pants were investigated in a standardized manner. Death/hospitali-
zation events were reported by the local center to study
investigators. For hospitalizations and deaths occurring in hospital,
hospital records including the narrative summary, selected physician
notes, pertinent laboratory, imaging, and electrocardiogram data
were retrieved and abstracted by study personnel according to a
standardized procedure. In addition, for all deaths (in or out of
hospital), death certificates and autopsy results (where applicable)
were retrieved and abstracted.
Designation of exposures and outcomes
Per routine practice, ultrafiltration volume was measured as the
change in weight over the course of dialysis (i.e., pre-dialysis weight
minus post-dialysis weight). UFR was expressed in terms of ml/h/kg
by dividing the ultrafiltration volume by dialysis session length and
target weight.15,16 In the primary analysis, UFR was categorized as
p10ml/h/kg, 10–13ml/h/kg, and 413ml/h/kg based on precedent
in the literature.15,16 Secondary analysis considered a cubic spline
representation of UFR.
A blinded outcome review committee convened by the HEMO
investigators adjudicated cause of death (i.e., CV, non-CV). For each
death, records (collected as above) were reviewed by two committee
members; disagreements were settled by majority vote of the full
outcome committee.17 Attribution of cause of hospitalization was
adjudicated in an analogous manner. CV events were considered to
be those ascribed to ischemic heart disease; congestive heart failure;
arrhythmias and conduction problems; sudden cardiac death due to
heart conditions other than ischemic heart disease/arrhythmia;
Adjusted hazard ratio (95% CI)
CV hospitalization and all-cause mortality
10 ml/h/kg
10–13 ml/h/kg
>13 ml/h/kg
10–13 ml/h/kg
>13 ml/h/kg
CV hospitalization
10 ml/h/kg
10–13 ml/h/kg
>13 ml/h/kg
CV hospitalization and CV mortality
10 ml/h/kg
0.8 1 1.4 1.8
1.00 (ref.)
0.99 (0.83–1.16)
1.39 (1.16–1.67)
1.00 (ref.)
0.98 (0.81–1.18)
1.38 (1.12–1.70)
1.00 (ref.)
0.94 (0.77–1.15)
1.24 (0.99–1.56)
Figure 4 |Adjusted association between ultrafiltration rate (UFR) and (1) cardiovascular (CV) hospitalization and all-cause
mortality, (2) CV hospitalization and CV-related mortality, and (3) CV hospitalization. Based on Cox regression models adjusted for
age, sex, interdialytic weight gain, race (black, non-black), smoking status (never, past, current), vintage (o1, 1–2, 2–4,X4 years), access type
(graft, fistula, catheter), systolic blood pressure (o120, 120–140, 140–160, 160–180, X180mmHg), residual urine output (p versus
4200ml/day), diabetes, congestive heart failure, peripheral vascular disease, ischemic heart disease, cerebrovascular disease, serum
albumin, creatinine, hematocrit (o30, 30–33, 33–36, X36%), and phosphorus, and use of a-adrenergic blocker, angiotensin-converting
enzyme inhibitor/angiotensin receptor blocker, b-blocker, calcium channel blocker, nitrates, and other antihypertensives. Unadjusted
estimates (not shown) for the relationship between UFR (10–13 and 413ml/h/kg, respectively) and outcomes were: 0.88 (0.76–1.03;
P¼ 0.13) and 1.21 (1.05–1.40; P¼ 0.01) for CV hospitalization and all-cause mortality; 0.90 (0.76–1.08; P¼ 0.26) and 1.23 (1.05–1.45; P¼ 0.01)
for CV hospitalization and CV-related mortality; and 0.88 (0.73–1.06; P¼ 0.18) and 1.14 (0.96–1.36; P¼ 0.13) for CV hospitalization.
Abbreviations: ref., reference; CI, confidence interval.
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valvular defects; hypertensive crisis or accelerated hypertension;
cerebral vascular disease; and vascular disease, including ruptured
vascular aneurysm, peripheral vascular disease, mesenteric ischemia,
and arterial embolism/thrombosis.
Statistical analyses
All analyses were performed using STATA 10.0MP (College Station,
TX). Baseline subject characteristics were described as counts and
proportions for categorical variables and as means and s.d. for
continuous variables. Bivariable comparisons across UFR groups
were made using contingency table methods and w2-testing or
analysis of variance, as dictated by data type.
Baseline values of UFR (and covariates) were considered as the
mean of values prior to randomization (typically consisting of
between 1 and 4 measurements made over 4–6 weeks). Participants
were considered at-risk from their date of randomization until death
or censoring. Censoring events for analyses of all-cause mortality
and CV mortality were receipt of a kidney transplant and the end of
the study period (31 December 2001); for analyses of CV mortality,
death due to non-CV cause was considered as a censoring criterion
as well. For analyses considering hospitalization events, participants
were additionally censored at the time of study withdrawal, change
in dialytic modality, or transfer of care to a non-participating
dialysis center (hospitalization data were not available to investiga-
tors in these instances, whereas vital status was followed and
complete for all participants irrespective of these events).
Analogous methods were used to investigate the associations
between UFR and outcomes of interest: all-cause mortality, CV
mortality, CV hospitalization, and composites of these. Likelihood
ratio testing was used to assess for effect modification of the
association between UFR and outcomes on the basis of treatment
group assignment; as no significant interaction was detected, data
were pooled across (flux and dose) intervention groups (Supple-
mentary Table SB online). The unadjusted associations between
UFR and survival were estimated using Kaplan–Meier methods, log-
rank testing, and unadjusted Cox proportional hazards models.
Adjusted associations between UFR and survival were estimated
using multivariable Cox proportional hazards models with inclusion
of covariate terms for potential confounders. Covariates were
selected as those variables that might plausibly be associated with
both UFR and outcomes based on clinical precedent and evidence
from the literature. (In addition, we examined for potential
confounding on the basis of HEMO Study interventions (i.e., flux
and treatment groups); upon inclusion of these variables in the
statistical model, estimates of association between UFR and
outcomes were unchanged (Supplementary Table SA online),
indicating no confounding on this basis. Therefore, treatment
group assignments were not included in the final multivariable
models.) Specification of continuous covariates (linear versus
categorical) was guided by each covariate’s observed association
with outcome, as assessed by graphical evaluation of regression
coefficients, Akaike’s Information Criterion, and Martingale residual
plots. All models were stratified on clinical center; robust variance
estimates were used to account for clustering of observations within
unit. The proportionality assumption for each model was tested
graphically and by Schoenfeld residual testing; two-way time cross-
product terms were included for variables that violated the
proportionality assumption (e.g., albumin and systolic blood pressure).
In addition, we constructed a restricted cubic spline representa-
tion of UFR, with knots corresponding to 8, 10, 12, and 14ml/h/kg,
measuring the associations with all-cause and CV mortality in a
manner otherwise analogous. Cubic splines provide a flexible
mechanism by which to model continuous predictors. Splines are
created by fitting a series of cubic polynomials between data points
to form a smooth curve that assesses change over intervals of the
exposure variable (i.e., UFR); thus, providing an alternative to
categorical and continuous organization of a predictor, which can
more faithfully reflect the observed data.
Effect modification of the UFR–survival association on the basis
of residual urine output, arterial disease (coronary, cerebrovascular,
or peripheral vascular), and congestive heart failure was explored by
introduction of two-way interaction terms (e.g., UFR congestive
heart failure) into the primary multivariable model (separately);
significance was assessed using likelihood ratio testing with a
nominal two-tailed P-value of 0.10 to account for the relative
insensitivity of these tests.
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